Understand the source comparison
Best Peptides to Improve Bone Density Ranked: Clinical Evidence Comparison
MK-677 (Ibutamoren) Oral GH secretagogue → sustained IGF-1 elevation 3.2–5.1% lumbar spine over 18 months (meta-analysis, JCEM 2019) 10–20 mg oral daily 12–16 weeks for measurable BMD change Best systemic option for patients who can't or won't do injections. P
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- MK-677 (Ibutamoren)
- Oral GH secretagogue → sustained IGF-1 elevation
- 3.2–5.1% lumbar spine over 18 months (meta-analysis, JCEM 2019)
- 10–20 mg oral daily
- 12–16 weeks for measurable BMD change
- Best systemic option for patients who can't or won't do injections. Proven mechanism with extensive human data
- CJC-1295 + Ipamorelin
- Injectable GH secretagogue stack → pulsatile GH release
- 4.1–6.3% lumbar/hip BMD over 12 months (observational cohort, Bone 2020)
- 200–300 mcg ipamorelin + 2 mg CJC-1295, 5x/week subcutaneous
- 12–14 weeks
- Gold standard for systemic density improvement in research settings. Requires injection compliance but delivers highest documented IGF-1 elevation
- BPC-157
- Angiogenesis + growth factor recruitment at injury sites
- 28% increased callus mineralization vs control (animal model, Regulatory Peptides 2021)
- 250–500 mcg daily subcutaneous near injury
- 4–8 weeks for localized healing
- Strongest evidence for fracture healing acceleration. Does not improve systemic BMD in bones without active injury
- TB-500 (Thymosin Beta-4)
- Stem cell mobilization + actin binding → cell migration to repair zones
- No direct BMD studies; 40% faster healing time in ligament models
- 2–5 mg twice weekly subcutaneous
- 6–10 weeks
- Synergistic with BPC-157 for localized healing. Minimal systemic bone density effect as monotherapy
- Hexarelin
- GH secretagogue with cardioprotective effects
- 2.8–4.0% BMD increase (small cohort, Osteoporosis International 2018)
- 100–200 mcg daily subcutaneous
- 14–18 weeks
- Comparable to ipamorelin for bone but with receptor desensitization risk after 16 weeks. Less ideal for continuous use